{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:13:45Z","timestamp":1783120425450,"version":"3.54.6"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017255","name":"Allergy Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017255","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["205687"],"award-info":[{"award-number":["205687"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019851","name":"Aldeyra Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.anai.2022.04.004","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T10:10:13Z","timestamp":1649412613000},"page":"160-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps"],"prefix":"10.1016","volume":"129","author":[{"given":"Larry","family":"Borish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam A.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Chupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wagenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana R.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhabita","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Yancey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wytske","family":"Fokkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.anai.2022.04.004_bib0001","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.jaci.2013.02.036","article-title":"Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology","volume":"131","author":"Akdis","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2022.04.004_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"issue":"5","key":"10.1016\/j.anai.2022.04.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.02.023","article-title":"Clinical research needs for the management of chronic rhinosinusitis with nasal polyps in the new era of biologics: a National Institute of Allergy and Infectious Diseases workshop","volume":"8","author":"Naclerio","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2022.04.004_bib0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/0145561320964653","article-title":"The role of biologics in chronic rhinosinusitis with nasal polyps","volume":"100","author":"Patel","year":"2021","journal-title":"Ear Nose Throat J"},{"issue":"1","key":"10.1016\/j.anai.2022.04.004_bib0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2022.04.004_bib0006","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2022.04.004_bib0007","unstructured":"Nucala EMA. (Mepolizumab) summary of product characteristics 2021. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf. Accessed December 8, 2021."},{"key":"10.1016\/j.anai.2022.04.004_bib0008","unstructured":"GlaxoSmithKline, NUCALA. (Mepolizumab) prescribing information. Available at: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF. Accessed August 24, 2021."},{"key":"10.1016\/j.anai.2022.04.004_bib0009","unstructured":"GlaxoSmithKline. Nucala (mepolizumab) prescribing information, Japan. Available at: https:\/\/gskpro.com\/ja-jp\/products-info\/nucala\/index\/. Accessed June 1, 2021."},{"key":"10.1016\/j.anai.2022.04.004_bib0010","unstructured":"Regeneron. Dupixent (dupilumab) prescribing information. Available at: https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf. Accessed August 24, 2021."},{"key":"10.1016\/j.anai.2022.04.004_bib0011","unstructured":"Roche. FDA approves Xolair (omalizumab) for adults with nasal polyps. Available at: https:\/\/www.roche.com\/investors\/updates\/inv-update-2020-12-01b.htm. Accessed July 21, 2021."},{"key":"10.1016\/j.anai.2022.04.004_bib0012","unstructured":"Sanofi. FDA approves Dupixent (dupilumab) for chronic rhinosinusitis with nasal polyposis. Available at: https:\/\/www.sanofi.com\/-\/media\/Project\/One-Sanofi-Web\/Websites\/Global\/Sanofi-COM\/Home\/media-room\/press-releases\/2019\/2019-06-26-19-30-00-1874771-en.pdf. Accessed July 21, 2021."},{"issue":"4","key":"10.1016\/j.anai.2022.04.004_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2022.04.004_bib0014","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10209","key":"10.1016\/j.anai.2022.04.004_bib0015","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2022.04.004_bib0016","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.04.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022644","article-title":"Chronic rhinosinusitis: a qualitative study of patient views and experiences of current management in primary and secondary care","volume":"9","author":"Vennik","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.anai.2022.04.004_bib0018","doi-asserted-by":"crossref","unstructured":"Hopkins C, Lee SE, Klimek L, Soler ZM. Clinical assessment of chronic rhinosinusitis [e-pub ahead of print]. J Allergy Clin Immunol Pract. https:\/\/doi.org\/10.1016\/j.jaip.2022.02.008, Accessed March 16, 2022.","DOI":"10.1016\/j.jaip.2022.02.008"},{"issue":"4","key":"10.1016\/j.anai.2022.04.004_bib0019","first-page":"183","article-title":"Staging in rhinosinusitus","volume":"31","author":"Lund","year":"1993","journal-title":"Rhinology"},{"issue":"1","key":"10.1016\/j.anai.2022.04.004_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/194589240501900116","article-title":"Correlation between preoperative symptom scores, quality-of-life questionnaires, and staging with computed tomography in patients with chronic rhinosinusitis","volume":"19","author":"Wabnitz","year":"2005","journal-title":"Am J Rhinol"},{"issue":"2","key":"10.1016\/j.anai.2022.04.004_bib0021","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4193\/Rhino15.072","article-title":"Stratification of SNOT-22 scores into mild, moderate or severe and relationship with other subjective instruments","volume":"54","author":"Toma","year":"2016","journal-title":"Rhinology"},{"issue":"5","key":"10.1016\/j.anai.2022.04.004_bib0043","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2500\/ajra.2015.29.4231","article-title":"Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population","volume":"29","author":"Lou","year":"2015","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"10.1016\/j.anai.2022.04.004_bib0044","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12931-019-1056-4","article-title":"Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis","volume":"20","author":"Prazma","year":"2019","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.anai.2022.04.004_bib0045","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3758\/BF03210709","article-title":"Internal consistency reliability of the fractionated and whole University of Pennsylvania Smell Identification Test","volume":"45","author":"Doty","year":"1989","journal-title":"Percept Psychophys"},{"issue":"5","key":"10.1016\/j.anai.2022.04.004_bib0032","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"issue":"5","key":"10.1016\/j.anai.2022.04.004_bib0033","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/coa.13177","article-title":"Minimal clinically important difference for the 22-item Sinonasal Outcome Test in medically managed patients with chronic rhinosinusitis","volume":"43","author":"Phillips","year":"2018","journal-title":"Clin Otolaryngol"},{"issue":"5","key":"10.1016\/j.anai.2022.04.004_bib0034","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/alr.22269","article-title":"Determinants of noticeable symptom improvement despite sub-MCID change in SNOT-22 score after treatment for chronic rhinosinusitis","volume":"9","author":"Phillips","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.anai.2022.04.004_bib0046","unstructured":"Washington University School of Medicine. Sino-nasal outcome Test (SNOT-22). Available at: https:\/\/www.canvasc.ca\/pdf\/SNOT22.pdf. Accessed July 21, 2021."},{"issue":"2","key":"10.1016\/j.anai.2022.04.004_bib0047","doi-asserted-by":"crossref","first-page":"AB126","DOI":"10.1016\/j.jaci.2020.12.462","article-title":"Mepolizumab reduces disease symptoms for patients with chronic rhinosinusitis with nasal polyps: data from the SYNAPSE study","volume":"147","author":"Tabberer","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2022.04.004_bib0022","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/lary.25223","article-title":"Can surgeons predict the olfactory outcomes after endoscopic surgery for nasal polyposis?","volume":"125","author":"Nguyen","year":"2015","journal-title":"Laryngoscope"},{"issue":"11","key":"10.1016\/j.anai.2022.04.004_bib0023","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1111\/all.14408","article-title":"Real-life assessment of chronic rhinosinusitis patients using mobile technology: the mySinusitisCoach project by EUFOREA","volume":"75","author":"Seys","year":"2020","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2022.04.004_bib0024","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2500\/ajr.2008.22.3222","article-title":"Impact of chronic rhinosinusitis and endoscopic sinus surgery on bone remodeling of the paranasal sinuses","volume":"22","author":"Cho","year":"2008","journal-title":"Am J Rhinol"},{"issue":"1","key":"10.1016\/j.anai.2022.04.004_bib0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1110-2098.132296","article-title":"Assessment of fibroproliferative healing after functional endoscopic sinus surgery","volume":"27","author":"Ragab","year":"2014","journal-title":"Menoufia Med J"},{"issue":"5","key":"10.1016\/j.anai.2022.04.004_bib0026","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/lio2.303","article-title":"A structured histopathology-based analysis of surgical outcomes in chronic rhinosinusitis with and without nasal polyps","volume":"4","author":"Marino","year":"2019","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"8","key":"10.1016\/j.anai.2022.04.004_bib0027","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/alr.21754","article-title":"Clinical implications of mucosal remodeling from chronic rhinosinusitis","volume":"6","author":"Do","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"issue":"3","key":"10.1016\/j.anai.2022.04.004_bib0028","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.amjoto.2019.03.014","article-title":"Histopathologic analysis in chronic rhinosinusitis: impact on quality of life outcomes","volume":"40","author":"Wang","year":"2019","journal-title":"Am J Otolaryngol"},{"issue":"4","key":"10.1016\/j.anai.2022.04.004_bib0029","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2022.04.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2022.04.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2022.04.004_bib0035","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/alr.22780","article-title":"Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"11","author":"Hopkins","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"10.1016\/j.anai.2022.04.004_bib0036","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.04.004_bib0037","first-page":"151","article-title":"State-of-the-art overview on biological treatment for CRSwNP","volume":"59","author":"Hellings","year":"2021","journal-title":"Rhinology"},{"issue":"4","key":"10.1016\/j.anai.2022.04.004_bib0038","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.iac.2018.06.006","article-title":"Biomarkers in chronic rhinosinusitis with nasal polyps","volume":"38","author":"Workman","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.anai.2022.04.004_bib0039","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.anai.2022.04.004_bib0040","unstructured":"US Food and Drug Administration. Adaptive designs for clinical trials of drugs and biologics: guidance for industry. 2019. Available at: https:\/\/www.fda.gov\/media\/78495\/download. Accessed August 24, 2021."},{"issue":"3","key":"10.1016\/j.anai.2022.04.004_bib0041","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6","key":"10.1016\/j.anai.2022.04.004_bib0042","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for severe eosinophilic asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622003003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622003003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:29:08Z","timestamp":1761053348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622003003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1081120622003003"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2022.04.004","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2022.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}